Cell Therapy (Yescarta and Tecartus)
Q2 2026 cell therapy sales fell 14% to $417 million.
The numbers
What it is
Gilead's Kite unit sells CAR T-cell cancer therapies: Yescarta for large B-cell lymphoma and Tecartus for mantle cell lymphoma. Total cell therapy sales were $1.84 billion in 2025, down 7%, and Q2 2026 sales were down 14%.
Why it matters to the stock. Cell therapy is a shrinking part of revenue. The anito-cel acquisition brings a next-generation myeloma CAR T-cell product into the same business.
News
Gilead agrees to buy Arcellx for $115 per share in cash plus CVR, about $7.8 billion
Gilead agreed to acquire the rest of Arcellx, the partner on anito-cel, a BCMA-directed CAR T-cell therapy for multiple myeloma.
M&A